The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 06, 2018
Filed:
Dec. 07, 2012
Biotest Ag, Dreieich, DE;
Immunogen, Inc., Waltham, MA (US);
Gregor Schulz, Umkirch, DE;
Frank Osterroth, Dietzenbach, DE;
Thomas Haeder, Dreieich, DE;
Christoph Bruecher, Eschborn, DE;
Gabriele Niemann, Walzbachtal, DE;
Andre Engling, Bad Homburg, DE;
Christoph Uherek, Seligenstadt, DE;
Benjamin Daelken, Frankfurt am Main, DE;
Andrea Wartenberg-Demand, Schrecksbach, DE;
Chantal Zuber, Ulm, DE;
Marcus Gutscher, Langen, DE;
Katrin Bernoester, Wiesbaden, DE;
Martin Koenig, Wiesbaden, DE;
BIOTEST AG, , DE;
IMMUNOGEN INC., Waltham, MA (US);
Abstract
Disclosed is a method and composition for treating a disease associated with target cells expressing CD138 in a multiple dose regimen. An immunoconjugate comprising an engineered targeting antibody targeting CD138 expressing cells and an effector molecule is administered in a multiple dose regimen. The multiple dose regimen comprises at least two doses and the aggregate dose administered within an active treatment cycle is an aggregate maximum tolerable dose (AMTD) or a fraction of the AMTD. The AMTD and/or said fraction exceeds the dose resulting in dose limiting toxicity (DLT) and/or exceeds the maximum tolerable dose (MTD) when the immunoconjugate is administered as a single dose, including as part of a multiple single dose regimen within said active treatment cycle.